Irbesartán/Hidroclorotiazida Sandoz

Irbesartan, the active ingredient in Irbesartán/Hidroclorotiazida Sandoz, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with hydrochlorothiazide, and is indicated for adults requiring blood pressure control.

GNH USA supplies Irbesartán/Hidroclorotiazida Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality, regulatory compliance and timely delivery across multiple continents. The company adheres to stringent quality‑assurance protocols and provides comprehensive documentation for regulatory submissions.

Irbesartan/Hydrochlorothiazide is employed to manage hypertension, a chronic condition characterized by elevated arterial pressure. - Essential hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile. - Hypertension with fluid retention: provides combined antihypertensive and diuretic effect to lower volume overload. - Hypertension requiring an angiotensin II receptor blocker and thiazide diuretic: simplifies therapy by delivering both agents in one tablet. - Resistant hypertension: offers additional blood pressure reduction when monotherapy is insufficient. - Hypertension with concomitant edema: the diuretic component helps reduce fluid overload.

Irbesartan/Hydrochlorothiazide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache, often mild and transient. - Increased urination due to the diuretic effect. - Electrolyte disturbances such as low potassium or sodium levels. - Fatigue or general weakness. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension leading to fainting or shock. - Angioedema or swelling of the face, lips, tongue or throat. - Acute kidney injury or a rapid rise in serum creatinine. - Hyperkalemia or dangerously high potassium levels. - Blood dyscrasias such as agranulocytosis or thrombocytopenia.

When prescribing Irbesartan/Hydrochlorothiazide, clinicians should observe several precautionary measures to ensure safe use. - Monitor blood pressure: check regularly to avoid excessive hypotension. - Assess renal function: evaluate serum creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium and sodium levels due to diuretic effect. - Use caution in patients with hepatic impairment: dose adjustment may be required. - Avoid in severe hyperkalemia or anuria: contraindicated in these conditions. - Store at ambient temperature: keep in original packaging, protect from moisture.

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use may increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: can cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive effects on potassium and renal function. - Lithium: increased lithium levels and toxicity risk. - NSAIDs (high dose): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: diuretic may affect glucose control, requiring dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): may increase hydrochlorothiazide plasma levels. - Other antihypertensives: additive blood pressure lowering, monitor for hypotension.